Table 2 Patient Characteristics
Characteristics | Safety set | Immunologic set |
|---|---|---|
n = 12 | n = 11 | |
Age in years, median (range) | 48 (31, 62) | 49 (31, 62) |
| Â | n (%) | n (%) |
Gender | ||
 Female | 12 (100%) | 11 (100%) |
Race | ||
 Caucasian | 12 (100%) | 11 (100%) |
Ethnicity | ||
 Non-Hispanic | 12 (100%) | 11 (100%) |
Menopausal Status | ||
 Post-menopausal | 8 (67%) | 7 (64%) |
 Pre-menopausal | 4 (33%) | 4 (33%) |
Pathologic Type | ||
 Ductal | 11 (92%) | 11 (100%) |
 Unknown | 1 (8%) |  |
Histologic Grade | ||
 Grade II | 3 (25%) | 3 (27%) |
 Grade III | 8 (67%) | 7 (64%) |
 Unknown | 1 (8%) | 1 (9%) |
Stage | ||
 II | 3 (25%) | 3 (27%) |
 III | 9 (75%) | 8 (73%) |
ER Status | ||
 Negative | 5 (42%) | 5 (45%) |
 Positive | 7 (58%) | 6 (55%) |
PR Status | ||
 Negative | 6 (50%) | 6 (55%) |
 Positive | 6 (50%) | 5 (45%) |
Her 2/Neu Status | ||
 Negative | 6 (50%) | 5 (45%) |
 Positive | 5 (42%) | 5 (45%) |
 Unknown | 1 (8%) | 1 (9%) |
On Hormonal Therapy | ||
 No | 6 (50%) | 5 (45%) |
 Yes | 6 (50%) | 6 (55%) |
 Type | ||
  Arimidex | 3 | 3 |
  Tamoxifen | 3 | 3 |
HLA type (may be multiple) | ||
 A1 | 7 (58%) | 7 (64%) |
 A2 | 5 (42%) | 4 (36%) |
 A3 | 6 (50%) | 6 (55%) |